• News & Events

NEWS

LimFlow Expands Senior Management Team and Opens Silicon Valley Office06.06.2017

LimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients26.04.2017

LimFlow Receives CE Mark for Purely Percutaneous Critical Limb Ischemia (CLI) Technology Designed to Restore Perfusion for “No Option” Patient.15.11.2016

LimFlow Announces Presentation of the LimFlow Procedure at a Dedicated Symposium During the Leipzig Interventional Course, LINC 2015 – January 27-30, 201515.12.2014

Dresden Germany 15 December 2014 -- LimFlow today announced that Drs. Andrej Schmidt and Jihad Mustapha will be chairing a session on the LimFlow procedure for treating Critical Limb Ischemia at the upcoming Leipzig Interventional Course or LINC on Tuesday 27 January 2015 starting at 16:00 CET (www.leipzig-interventional-course.com) .

Download a schedule of the talks.

About LimFlow GmbH
LimFlow is a private, venture-backed medical device company offering a novel therapeutic to treating Critical Limb Ischemia. LimFlow is enrolling patients into its feasibility clinical study using its patented Percutaneous Deep Vein Arterialization in Singapore and Leipzig Germany with its CE Mark trial to being in early 2015.

LimFlow Announces the Closing of its Series A Financing30.09.2014

Dresden Germany 30 September, 2014 -- LimFlow today announced that it has closed its Series A financing with a major Family Fund leading the round. The terms and amount were not discussed.

About LimFlow GmbH
LimFlow is a private, venture-backed medical device company offering a novel therapeutic to treating Critical Limb Ischemia. LimFlow is enrolling patients into its feasibility clinical study using its patented Percutaneous Deep Vein Arterialization in Singapore and Leipzig Germany with its CE Mark trial to being in early 2015.

For more information about LimFlow, please visit www.LimFlow.com. The LimFlow System is not approved for sale in Europe and is not approved for sale or investigational use in the United States. For additional information, contact Tim Lenihan, CEO, LimFlow GmbH ; tim@limflow.com or +49 173 356 8405.

LimFlow Announces Presentation of the LimFlow Procedure at the 4th Annual Amputation Prevention Symposium, 13-16 August 201413.08.2014

Dresden Germany 13 August, 2014 -- LimFlow today announced that Dr. Steven Kum will Present his First-In-Man Experience with Percutaneous Deep Vein Arterialization (The LimFlow Procedure) at the 4th Annual Amputation Prevention Symposium, 13-16 August 2014.

About LimFlow GmbH
LimFlow is a private, venture-backed medical device company offering a novel therapeutic to treating Critical Limb Ischemia. LimFlow is enrolling patients into its feasibility clinical study using its patented Percutaneous Deep Vein Arterialization in Singapore and Leipzig Germany with its CE Mark trial to being in early 2015.

For more information about LimFlow, please visit www.LimFlow.com. The LimFlow System is not approved for sale in Europe and is not approved for sale or investigational use in the United States. For additional information, contact Tim Lenihan, CEO, LimFlow GmbH ; tim@limflow.com or +49 173 356 8405.

EVENTS